MARVEL BIOSCIENCES CORP (MRVL.CA) Stock Price & Overview
TSX-V:MRVL • CA57384M1077
The current stock price of MRVL.CA is 0.145 CAD. Today MRVL.CA is up by 3.57%. In the past month the price increased by 3.57%.
MRVL.CA Key Statistics
- Market Cap
- 8.41M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
MRVL.CA Stock Performance
MRVL.CA Stock Chart
MRVL.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MRVL.CA. When comparing the yearly performance of all stocks, MRVL.CA is a bad performer in the overall market: 82.62% of all stocks are doing better.
MRVL.CA Earnings
MRVL.CA Forecast & Estimates
MRVL.CA Financial Highlights
Over the last trailing twelve months MRVL.CA reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -30.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -333.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRVL.CA Ownership
About MRVL.CA
Company Profile
Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
Company Info
IPO: 2019-02-28
MARVEL BIOSCIENCES CORP
Suite 420, 505 8th Avenue S.W.
Calgary ALBERTA CA
Employees: 0
Phone: 14037702469
MARVEL BIOSCIENCES CORP / MRVL.CA FAQ
What does MRVL do?
Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm develops new synthetic chemical derivatives of the original approved drug for the new disease indication. The company has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The firm is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
What is the current price of MRVL stock?
The current stock price of MRVL.CA is 0.145 CAD. The price increased by 3.57% in the last trading session.
What is the dividend status of MARVEL BIOSCIENCES CORP?
MRVL.CA does not pay a dividend.
How is the ChartMill rating for MARVEL BIOSCIENCES CORP?
MRVL.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How many employees does MARVEL BIOSCIENCES CORP have?
MARVEL BIOSCIENCES CORP (MRVL.CA) currently has 0 employees.